Heart Failure


AHA & AstraZeneca Push for Uptake of SGLT2 Inhibitors with TRANSLATE-HF Program

November 18, 2020

TRANSLATE-HF is a collaborative effort between the AHA and AstraZeneca with the goal of increasing and optimizing SGLT2 inhibitor use in US patients. Hear further insight lead author from the first of 6 TRANSLATE-HF studies, which was presented at AHA 2020.

Sotagliflozin, a Dual SGLT2/1 Inhibitor, Shows Promise in Phase 3 Trials

November 17, 2020

Data from the phase 3 SOLOIST-WHF and SCORED trials suggest sotagliflozin was associated with significant reductions in death from CVD in patients with worsening heart failure and significant reductions in blood glucose levels among patients with moderate to severe kidney impairment.

Should Men and Women with HFpEF be Treated Differently?

November 14, 2020

Professor John McMurray offers insight into a discussion he led at AHA 2020 exploring the notion that treatment of men and women with heart failure with preserved ejection fraction should be approached differently.